HiDEF-seq advances cancer treatment:
HiDEF-seq technique could further help develop or advance new prevention approaches or develop treatments for genetic diseases and even cancer.
Gilad Evrony, senior study author and a core member of the Center for Human Genetics & Genomics at NYU Grossman School of Medicine told Science Direct:
The DNA a woman is born with may influence how her cells respond to chromosomal abnormalities acquired with aging, according to a new genomic analysis co-led by NCI researchers.
A protocol is described for generating human brain assembloids and performing viral labeling and retrograde tracing, 3D live imaging of axon projection and optogenetics with calcium imaging and electrophysiological recordings to model neural circuits.
The reason targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked, has been discovered by researchers from UCL, the Francis Crick Institute and AstraZeneca.
The study, published in Nature Communications, shows that lung cancer cells with two particular genetic mutations are more likely to double their genome, which helps them to withstand treatment and develop resistance to it.
In the UK, lung cancer is the third most common type of cancer and the leading cause of cancer death. Around 85% of patients with lung cancer have non-small cell lung cancer (NSCLC), and this is the most common type found in patients who have never smoked. Considered separately, “never smoked” lung cancer is the fifth-most common cause of cancer death in the world.
The gene-editing technique employs prime editors along with advanced enzymes known as recombinases. This method has the potential to lead to universal gene therapies that are effective for conditions like cystic fibrosis.
Researchers at the Broad Institute of MIT and Harvard have enhanced a gene-editing technology that can now efficiently insert or replace entire genes in human cell genomes, potentially making it suitable for therapeutic uses.
The advance, from the lab of Broad core institute member David Liu, could one day help researchers develop a single gene therapy for diseases such as cystic fibrosis that are caused by one of hundreds or thousands of different mutations in a gene. Using this new approach, they would insert a healthy copy of the gene at its native location in the genome, rather than having to create a different gene therapy to correct each mutation using other gene-editing approaches that make smaller edits.
Cell division is a crucial process for all life forms, from bacteria to blue whales, enabling growth, reproduction, and the continuation of species. Despite its universal nature, the methods of cell division vary significantly across organisms. A recent study by EMBL Heidelberg’s Dey group, along with their collaborators and published in Nature, investigates the evolution of cell division methods in organisms closely related to fungi and animals. For the first time, this research demonstrates the connection between an organism’s life cycle and its cell division techniques.
Despite last sharing a common ancestor over a billion years ago, animals and fungi are similar in many ways. Both belong to a broader group called ‘eukaryotes’ – organisms whose cells store their genetic material inside a closed compartment called the ‘nucleus’. The two differ, however, in how they carry out many physiological processes, including the most common type of cell division – mitosis.
Most animal cells undergo ‘open’ mitosis, in which the nuclear envelope – the two-layered membrane separating the nucleus from the rest of the cell – breaks down when cell division begins. However, most fungi use a different form of cell division – called ‘closed’ mitosis – in which the nuclear envelope remains intact throughout the division process. However, very little is known about why or how these two distinct modes of cell division evolved and what factors determine which mode would be predominantly followed by a particular species.
Summary: A new study uncovered how epigenetic marks and the Cux2 protein influence brain folding. The study reveals that the epigenetic mark H3K27ac and Cux2 are key to forming the cerebral cortex’s gyri and sulci.
These findings enhance our understanding of brain development and could inform treatments for brain malformations. The research underscores the complexity of the nervous system and the pivotal role of epigenetics in brain structure.
The CRISPR-Cas9 system has revolutionised gene-editing, but cutting DNA isn’t all it can do. From turning gene expression on and off to fluorescently tagging particular sequences, this animation explores some of the exciting possibilities of CRISPR.
Download a poster on ‘The expanding CRISPR toolbox’ here: https://www.nature.com/posters/crispr…
Produced with support from Dharmacon: https://www.dharmacon.com.
Nature has full responsibility for all editorial content, including Nature Video content. This content is editorially independent of sponsors.
Is Director, Infectious Disease Preparedness and Response, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services (https://aspr.hhs.gov/Pages/Home.aspx).
The HHS Administration for Strategic Preparedness and Response (ASPR) leads the nation’s medical and public health preparedness for, response to, and recovery from disasters and other public health emergencies.
ASPR collaborates with hospitals, healthcare coalitions, biotech firms, community members, state, local, tribal, and territorial governments, and other partners across the country to improve readiness and response capabilities.
Dr. Boucher previously held several other critical roles in the organization, including as Chief of the Antivirals \& Antitoxins branch at BARDA’s Anthrax, Botulinum, Ebola and Smallpox therapeutics program office, Acting Director for the Administration for Strategic Preparedness and Response’s Office of Industrial Base Management and Supply Chain (IBM/SC) and serving as HHS’s lead negotiator for product development/procurement agreements for COVID-19 medical countermeasures.
Dr. Boucher has a Bachelor of Science (B.S.), Genetics, and a Doctor of Philosophy (PhD), Biochemistry and Molecular Biology from University of California, Davis.
Two new therapies—one which uses the gene-editing technology—treat sickle cell anemia.
